Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sevelamer hydrochloride (Renagel) vs calcium acetate in peritoneal dialysis patients
2004-002174-32Phase 3Completed
- Sponsor
- Sanofi
- Start
- Nov 2004
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of sevelamer carbonate in end-stage kidney disease (ESKD) and hyperphosphatemia (2 arms), sponsored by Sanofi. Primary endpoint: Change in serum phosphorus. Started Nov 2004; status: completed.
02
Drugs
sevelamer carbonate
03
Conditions
end-stage kidney disease (ESKD)hyperphosphatemia
Beyond the preview
Go deeper on 2004-002174-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002174-32.